Compare MELI & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MELI | VRTX |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8B | 96.6B |
| IPO Year | 2007 | 1991 |
| Metric | MELI | VRTX |
|---|---|---|
| Price | $2,024.01 | $452.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 25 |
| Target Price | ★ $2,873.89 | $494.64 |
| AVG Volume (30 Days) | 571.2K | ★ 1.4M |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.68 | N/A |
| EPS | ★ 40.97 | 14.22 |
| Revenue | ★ $26,193,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $40.30 | $11.01 |
| Revenue Next Year | $28.24 | $8.74 |
| P/E Ratio | $49.30 | ★ $31.35 |
| Revenue Growth | ★ 36.94 | 10.33 |
| 52 Week Low | $1,646.00 | $362.50 |
| 52 Week High | $2,645.22 | $519.68 |
| Indicator | MELI | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 60.22 |
| Support Level | $1,957.00 | $433.81 |
| Resistance Level | $2,163.00 | $463.85 |
| Average True Range (ATR) | 64.49 | 10.54 |
| MACD | 0.65 | 0.55 |
| Stochastic Oscillator | 36.47 | 74.27 |
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.